Your Health, We Care
Release date: 2024-08-09 13:59:11 Recommended: 150
Exkivity works by binding to and blocking EGFR exon 20 insertion mutations, which helps to slow the growth of cancer cells.
Exkivity may interact with other medications during treatment, and these interactions may affect its safety and efficacy.
Exkivity itself is weak in its inhibition of CYP3A, but may still affect the metabolism of other CYP3A substrates in some cases.
When Exkivity is used in combination with other CYP3A substrates, blood concentrations and efficacy of these substrates should be closely monitored to avoid drug interactions due to metabolic alterations.
Coadministration of Exkivity with CYP3A substrates may decrease plasma concentrations of CYP3A substrates, which may reduce the efficacy of these substrates.
The drug-drug interaction of CYP3A substrates with Exkivity is a complex issue that requires a combination of factors. When using Exkivity, the patient's drug history and risk of drug interactions should be carefully assessed, and appropriate precautions should be taken to ensure safe and effective treatment.
1. Avoid concomitant use of hormonal contraceptives with Exkivity.
2. Avoid concomitant use of Exkivity with other CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures. If concomitant use is unavoidable, increase the CYP3A substrate dosage in accordance with the approved product Prescribing Information.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
